Abstract
Antibiotic-resistant Escherichia coli strains including extended-spectrum β-lactamase (ESBL) isolates are globally widespread in medical, food, and environmental sources. Some of these strains are considered the most pathogenic bacteria in humans. The present work examined the predominance of antibiotic resistance in E. coli strains in wound infections comparing with E. coli strains isolated from a raw milk as a potential source of those strains. The wound infections included abdomen, anus, arm, back, buttock, chest, foot, hand, head, leg, lung, mouth, neck, penis, thigh, toe, and vagina infections. In total, 161 and 153 isolates identified as E. coli were obtained from wound infections and raw milk, respectively. A Vitek 2 system innovated by bioMérieux, France was applied to perform the identification and susceptibility tests. The E. coli isolates that have ability to produce ESBL were detected by an ESBL panel and NO45 card (bioMérieux). Over half of the E. coli were from abdomen, back, and buttock wound infections. More than 50%of the E. coli isolates obtained from wound infections were resistant to cefazolin, ampicillin, cefuroxime, ciprofloxacin, mezlocillin, moxifloxacin, piperacillin, and tetracycline; 70% of the isolates from wound infections and 0% of the isolates from raw milk were E. coli isolates produced ESBL. The data showed that the strains resistance to multi-antibiotic and produced ESBL are more widespread among wound infections than in raw milk.
Keywords: Escherichia coli, Wound infections, Antibiotics, Raw milk
1. Introduction
Escherichia coli is a gram-negative bacterium. Strains of E. coli are typically not pathogenic to humans. However, several E. coli strains have ability to cause several diseases in different sites including the renal system, gastrointestinal tract, and the central nervous system (Nataro and Kaper, 1998). Numerous strains of E. coli have evolved as opportunistic and commensal pathogens (Groisman and Ochman, 1996). Regrettably, several bacterial strains have become progressively resistant to antimicrobial agents over the last several decades (Guilfoile and Alcamo, 2007). Many international health institutions, such as World Health Organization and the United States Institute of Medicine, have formally expressed concern about the environmental and health hazards of antibiotic-resistant bacteria that pose health and economical risks (Meyer et al., 2010, Wise et al., 1998).
E. coli strains that are resistant to various antibiotics are of particular concern for global health so they are the most common uropathogenic and enteropathogenic bacteria. Unpasteurized milk is considered a main source of E. coli isolates resistance to multi- antibiotics. It has been confirmed that approximately 7% of E. coli isolates identified in raw milk are multi-drug resistant (Rasheed et al., 2014). A retrospective study that included more than 8900 bacterial isolates from milk reported an increasing prevalence of E. coli strains resistance to erythromycin (Makovec and Ruegg, 2003). The infections diagnosed in skin and soft tissue of patients almost at all ages are the most common among other microbial infections. Many cases of clinical wound infections may require treatment with antibiotics or parenteral therapy (Moet et al., 2007). It has been reported that 46%, 25%, and 21% of E. coli isolates that cause wound infections are resistant to ampicillin, tetracycline, and fluoroquinolones, respectively. E. coli isolates have many virulence factors that include outer membrane protease, cytotoxic necrotizing factor 1, drug resistance, and hemolysin (Petkovšek et al., 2009, Welch, 2016). A genetic analysis of E. coli isolates obtained from surgical incisions, traumatic injuries, and foot ulcers reported that 97.5%, 97.5%, 4%, 12.5%, 12.5%, and 2.5% of those isolates harbored the fimH, iutA, papC, hlyA, cnf1, and neuC gene, respectively (Chakraborty et al., 2017b). Most (90%) uropathogenic E. coli isolates possessed the fimH gene, followed by iutA (n = 98; 63%), papC (n = 76; 49%), cnf1 (n = 46; 29.5%), hlyA (n = 45; 29%), and neuC (n = 8; 5%), respectively (Chakraborty et al., 2017a).
The present work analyzed the prevalent patterns of E. coli strains resistance to multi-antibiotic from wound infections in patients treated at King Saud University Medical City (KSUMC) Riyadh, Saudi Arabia. The antibiotic resistance patterns were compared with E. coli strains that isolated from raw milk produced in the Riyadh region.
2. Material and methods
2.1. Microbial strains
The collection of E. coli isolates was performed between 02 October 2016 and 02 June 2017 at King Khaled University Hospital. Throughout this period, 227 wound infections samples were cultivated and identified agreeing with the directions of manufacturer using the full automatic system (Vitek 2 system). The types of wound infection and antibiotic resistance patterns were analyzed and compared with these data that obtained from bacterial isolates obtained from raw milk. The total number of milk samples collected in this study were 240. During the same time, the raw milk samples were collected weekly in a sterilized container at random from one of the companies producing milk in Riyadh, Saudi Arabia, identified here as company R. MacConkey agar (MCA), nutrient agar (NA), blood agar (BA), and violet red bile agar (VRBA) (Oxoid, UK) were used to isolate the bacterial strains (E. coli) based on culture characteristics. The primary identification was carried out using API 20 E (bioMerieux) and the identification was completed using the Vitek ®2 GN ID.
2.2. Determination of antimicrobial susceptibility
antibiotic susceptibility tests were done by the Vitek 2 system (bioMérieux) using several of cards including AST-GN69, AST-XN06, and AST-GN69, according to the instructions of manufacturer. One colony of each pure isolate on Blood medium (bloog agar base medium with 5% sheep blood) was tested. The purification of isolates was performed on previously described culture media at 35 °C for 20 h (Bobenchik et al., 2014).
2.3. Determination of extended-spectrum-β-lactamase (ESBL)
The Vitek 2 system was used to test ESBL in all the bacterial strains isolated in this work. A ESBL panel (NO45 card, bioMérieux) was applied. The panel consists of six wells, the first contains cefepime (1.0 μg/ml), the second contains cefotaxime (0.5 μg/ml), the third contains ceftazidime (0.5 μg/ml), the fourth contains cefepime + clavulanate (1.0 + 10 μg/ml), the fifth contains cefotaxime + clavulanate (0.5 + 4 μg/ml), and the sixth contains ceftazidime + clavulanate (0.5 + 4 μg/ml). Bacterial growth was recorded using spectrophotometric scanner. Decreasing in bacterial growth was determined by comparison between antibiotic alone with antibiotics + clavulanate. To perform the control test, E. coli ATCC 35,218 and ATCC 25,922 were employed.
2.4. Analysis of data
The statistical analysis of data was done by the Ward method, odds ratio and relative risk using SPSS statistical software. Correlation coefficients were determined as the square of the Pearson product using the Excel program.
3. Results
The results showed that 161 of 227 wound infections samples were identified as E. coli. The sources of wound infections included abdomen, anus, arm, back, buttock, chest, foot, hand, head, leg, lung, mouth, neck, penis, thigh, toe, and vagina. 39.8%, 14.2%, 14.2%, 8.5%, and 6.3% of the E. coli strains were obtained from the abdomen, buttock, back, foot, and anus, respectively, while other E. coli isolates were obtained in less than 5% of cases from wounds in the arm, chest, hand, head, leg, lung, mouth, neck, penis, thigh, toe, and vagina (Fig. 1). The data obtained from antibiotic susceptibility testing revealed that more than half of the E. coli strains from wound infections have the ability to resist the ampicillin, cefazolin, cefuroxime, ciprofloxacin, mezlocillin, moxifloxacin, piperacillin, and tetracycline, while more than half of the isolates were susceptible to amikacin, cefepime, cefoxitin, ertapenem, fosfomycin, gentamicin, imipenem, meropenem, tigecycline, tobramycin, piperacillin/tazobactam, trimethoprim/sulfamethoxazole, and amoxicillin/clavulanic acid. The data presented in Table 1 indicate that 81–100% of E. coli strains were susceptible to the standard antibiotics that applied in this research. However, while the isolates from raw milk showed susceptibility to most the tested standard antibiotics, it is conceivable that raw milk could still be a potential source of ampicillin, cefuroxime, and trimethoprim/sulfamethoxazole resistant E. coli isolates (see Fig. 2).
Fig. 1.
Percentage of E. coli isolates obtained from several different wound infection sites in patients treated at King Khaled University Hospital. (N = 161).
Table 1.
Antibiotic-resistant E. coli isolates from wound infections compared with the isolates from raw milk.
| From patients |
From raw milk |
||||||
|---|---|---|---|---|---|---|---|
| Antibiotics | S | R | I | S | R | I | RSQ |
| Amoxicillin/Clavulanic Acid | 62.4 | 23.0 | 14.6 | 100.0 | 0.0 | 0.0 | 0.97 |
| Ampicillin | 15.2 | 84.8 | 0.0 | 90.9 | 9.1 | 0.0 | 0.07 |
| Cefepime | 50.6 | 47.8 | 1.7 | 91.6 | 0.0 | 8.4 | 0.22 |
| Cefotaxime | 42.7 | 9.0 | 0.6 | 91.6 | 0.0 | 8.4 | 0.93 |
| Cefoxitin | 79.8 | 19.7 | 0.6 | 100.0 | 0.0 | 0.0 | 0.95 |
| Ceftazidime | 46.6 | 10.1 | 3.4 | 91.6 | 0.0 | 8.4 | 0.95 |
| Cefuroxime | 37.1 | 51.7 | 3.4 | 91.6 | 8.4 | 0.0 | 0.09 |
| Ciprofloxacin | 43.3 | 55.1 | 1.7 | 100.0 | 0.0 | 0.0 | 0.09 |
| Gentamicin | 74.2 | 25.8 | 0.0 | 100.0 | 0.0 | 0.0 | 0.88 |
| Imipenem | 99.4 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 1.00 |
| Meropenem | 100.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 1.00 |
| Piperacillin/Tazobactam | 87.6 | 7.3 | 5.1 | 100.0 | 0.0 | 0.0 | 1.00 |
| Tigecycline | 90.4 | 1.7 | 0.0 | 100.0 | 0.0 | 0.0 | 1.00 |
| Trimethoprim/sulfamethoxazole | 39.9 | 56.7 | 0.0 | 91.6 | 8.4 | 0.0 | 0.10 |
RSQ, Pearson correlation coefficient.
Fig. 2.
Percentage of antibiotic-resistant E. coli isolates from wound infections in patients treated at King Khaled University Hospital. (N = 161).
A dendrogram of a hierarchical cluster analysis of the antibiotic resistance patterns of bacterial strains isolated from wound infections and raw milk using Ward‘s method is presented in Fig. 3. E. coli isolates from wound infections were classified into seven groups. The first group (16.8% of the strains) was susceptible to almost all the standard antibiotics. The second group (12.4% of the strains) showed resistance to ampicillin, ciprofloxacin, gentamicin, levofloxacin, mezlocillin, moxifloxacin, piperacillin, tetracycline, and tobramycin. The third group (4.7% of the bacterial strains) showed resistance to amoxicillin/clavulanic acid, ampicillin, cefazolin, cefotaxime, and cefuroxime. The fourth group (15.5% of the bacterial strains) displayed resistance to ampicillin, mezlocillin, piperacillin, and tetracycline. The fifth group (10.6% of the bacterial strains) showed resistance to amoxicillin/clavulanic acid, ampicillin, cefazolin, cefepime, cefotaxime, ceftazidim, cefuroxime, mezlocillin, and piperacillin. The sixth group (21.7% of the bacterial isolates) showed resistance to ampicillin, cefazolin, cefepime, ceftazidim, cefuroxime, ciprofloxacin, gentamicin, mezlocillin, amoxicillin, piperacillin, tetracycline, and tobramycin. The seventh group (18.6% of the isolates) displayed resistance to ampicillin, cefazolin, cefepime, cefoxitin, ceftazidime, cefuroxime, levofloxacin, ciprofloxacin, mezlocillin, moxifloxacin, and piperacillin.
Fig. 3.
Dendrogram of a hierarchical cluster analysis of the antibiotic-resistant E. coli isolates from wound infections (N = 161) and raw milk (N = 153) using Ward‘s methods.
The analysis of the raw milk revealed five groups of E. coli isolates. Bacteria in the first group (47.1% of the bacterial strains) had no resistance to all tested antibiotics. The second group (17.6%) displayed intermediate resistance to amikacin. The third group (23.5%) displayed intermediate resistance to cefalotin. The fourth group (5.9%) displayed resistance to amoxicillin, ampicillin, cefalotin, cefixime, and aztreonam. The fifth group (5.9%) displayed resistance to trimethoprim/sulfamethoxazole, amoxicillin, and ampicillin. The data in Table 1 revealed high correlation coefficients between the E. coli isolates from wound infections and raw milk concerning the resistance and susceptible patterns for imipenem, meropenem, piperacillin/tazobactam, and tigecycline. Conversely, low correlation coefficients were evident for ampicillin, cefuroxime, and ciprofloxacin. Risk estimate between ampicillin resistant E coli and the part of body have been presented in Table 2, which show that odds ratios of abdomen, back, buttock and foot were 5.3, 4.65, 2.3 and 1.1 respectively. The Table 3 shows odds ratios and relative risk of the E coli strains isolated from raw milk that have resistance to ampicillin, cefuroxime and Trimethoprim/sulfamethoxazole. The data indicated that there is relative risk ranged from 6.66 to 10.01 and that the odds ratio ranged from 12.9 to 20.4.
Table 2.
Risk estimate between ampicillin resistant E coli and the part of body.
| Part of body | Odds ratio | 95% confidence interval (lower–upper) |
|---|---|---|
| Abdomen | 5.33 | 3.8–7.4 |
| Back | 4.65 | 0.6–35.97 |
| Buttock | 2.36 | 0.52–10.63 |
| Foot | 1.11 | 0. 23–5.25 |
| Anus | 0.26 | 0.07-0.975 |
| Vagina | 0.028 | 0.003–0.24 |
| Leg | 0.32 | 0.056–1.85 |
| Thigh | 0.05 | 0.05–4.99 |
| Chest | 0.16 | 0.01–2.75 |
| Penis | 0.98 (Cohort)* | 0.95–1.003 |
| Neck | 0.98 (Cohort)* | 0.96–1.005 |
| Toe | 0.99 (Cohort)* | 0.981–1.006 |
| Hand | 0.99 (Cohort)* | 0.981–1.006 |
| Head | 0.99 (Cohort)* | 0.981–1.006 |
If one of value is zero the odds ratio cannot apply, for this reason the cohort test analysis is sued to identify relationships between the ampicillin resistant E coli and the part of human body.
Table 3.
Risk estimate for antibiotics resistant E coli in wound infection and milk.
| Part of body | Odds ratio | 95% confidence interval (lower–upper) | Relative risk | 95% confidence interval (lower–upper |
|---|---|---|---|---|
| Ampicillin resistant E coli | 12.92 | 7.14–23.37 | 6.66 | 3.98–11.15 |
| Cefuroxime resistant E coli | 20.4 | 10.876–38.38 | 10.017 | 5.03–17.293 |
| Trimethoprim/sulfamethoxazole resistant E coli | 18.462 | 9.863–34.55 | 9.149 | 5.312–15.756 |
4. Discussion
The present research aimed to evaluate the prevalence of E. coli strains resistance to the standard antibiotic isolated from wound infections, and studied the correlation between those isolates and the antibiotic-resistant E. coli strains isolated from raw milk. Microbial infections caused by E. coli strains can cause illness and the bacteria can be transmitted through contaminated food or through contact with animals or people. In dairy factories, the workers often contact animals and raw milk. Furthermore, in Saudi Arabia and elsewhere, many dairy farmers are in daily contact with raw milk. For this reason, the study included raw milk as a source of antibiotic-resistant E. coli isolates. In recent years, a dramatic decline in the antibacterial susceptibility of medical E. coli isolates has been reported (Johnson and Russo, 2002, Petkovšek et al., 2009). The present data completely agree with these reports. The majority (70%) of the isolates from wound infections were ESBL-producing strains of E. coli compared with 0% of the bacterial strains that isolated from raw milk. The findings indicate that raw milk produced in the Riyadh Region is not a potential source of ESBL-producing strains of E. coli. It has been confirmed that the tetracycline, streptomycin, and ampicillin resistant E. coli strains identified in humans and bovines, with more than 50% of resistant isolates being multidrug resistant. The present findings concerning E. coli strains isolated from wound infections are consistent with prior observations (Wilkerson et al., 2004).
Antibiotic-resistant and E. coli isolates produced ESBL have been identified and investigated worldwide from several medical and environmental sources (Lautenbach et al., 2001, Rodríguez-Bano et al., 2004, Santman-Berends et al., 2017, Tansawai et al., 2018). The present work confirms that the strains of E. coli identified in wound infections and from raw milk displayed resistance to broad range of standard antimicrobial agents, and that the E. coli strains produced ESBL were prevalent in wound infections and not in raw milk. The majority (68.2%) of wound infections were from abdomen, back, and buttock infections. The percentage of multi-antibiotic resistant E. coli isolates from wound infections was more than that isolated from raw milk. ESBL-producing strains of E. coli were not identified in the tested raw milk. The present work concluded that antibiotics resistant E coli isolates infected the wounds in abdomen, back, buttock more than others body parties. In addition, the results confirmed that the raw milk could be resource of E coli isolates resistance to cefuroxime and the isolates that resistance to trimethoprim/sulfamethoxazole.
Acknowledgements
The authors extend their appreciation to the Localization and Development Technology Platform for the Infectious Diseases Surveillance and Detection Project at Kind Abdulaziz City for Science and Technology (KACST). The authors thank the Deanship of Scientific Research and RSSU at King Saud University for their technical support.
Disclosure Statement
There are No competing financial interests.
Footnotes
Peer review under responsibility of King Saud University.
References
- Bobenchik A.M., Deak E., Hindler J.A., Charlton C.L., Humphries R.M. Performance of VITEK® 2 for Antimicrobial Susceptibility Testing of Enterobacteriaceae with VITEK® 2 (2009 FDA) and 2014 CLSI Breakpoints. J. Clin. Microbiol. 2014 doi: 10.1128/JCM.02697-14. 02697 02614 JCM. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chakraborty A., Adhikari P., Shenoy S., Saralaya V. Molecular characterisation of uropathogenic Escherichia coli isolates at a tertiary care hospital in South India. Indian J. Med. Microbiol. 2017;35:305. doi: 10.4103/ijmm.IJMM_14_291. [DOI] [PubMed] [Google Scholar]
- Chakraborty A., Saralaya V., Adhikari P., Shenoy S. Virulence property, phylogenetic background, and resistance pattern of Escherichia coli isolates from wound infections. CHRISMED J. Health Res. 2017;4:248. [Google Scholar]
- Groisman E.A., Ochman H. Pathogenicity islands: bacterial evolution in quantum leaps. Cell. 1996;87:791–794. doi: 10.1016/s0092-8674(00)81985-6. [DOI] [PubMed] [Google Scholar]
- Guilfoile P., Alcamo I.E. Infobase Publishing; 2007. Antibiotic-resistant bacteria. [Google Scholar]
- Johnson J.R., Russo T.A. Uropathogenic Escherichia coli as agents of diverse non–urinary tract extraintestinal infections. J. Infect. Dis. 2002;186:859–864. doi: 10.1086/342490. [DOI] [PubMed] [Google Scholar]
- Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., Fishman N.O. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 2001;32:1162–1171. doi: 10.1086/319757. [DOI] [PubMed] [Google Scholar]
- Makovec J.A., Ruegg D.P.L. Antimicrobial resistance of bacteria isolated from dairy cow milk samples submitted for bacterial culture: 8,905 samples (1994–2001) J. Am. Vet. Med. Assoc. 2003;222:1582–1589. doi: 10.2460/javma.2003.222.1582. [DOI] [PubMed] [Google Scholar]
- Meyer E., Schwab F., Schroeren-Boersch B., Gastmeier P. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit. care. 2010;14:R113. doi: 10.1186/cc9062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moet G.J., Jones R.N., Biedenbach D.J., Stilwell M.G., Fritsche T.R. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004) Diagn Microbiol Infect Dis. 2007;57:7–13. doi: 10.1016/j.diagmicrobio.2006.05.009. [DOI] [PubMed] [Google Scholar]
- Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 1998;11:142–201. doi: 10.1128/cmr.11.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petkovšek Ž., Eleršič K., Gubina M., Žgur-Bertok D., Erjavec M.S. Virulence potential of Escherichia coli isolates from skin and soft tissue infections. J. Clin. Microbiol. 2009;47:1811–1817. doi: 10.1128/JCM.01421-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rasheed M.U., Thajuddin N., Ahamed P., Teklemariam Z., Jamil K. Antimicrobial drug resistance in strains of Escherichia coli isolated from food sources. Revista do Instituto de Medicina Tropical de São Paulo. 2014;56:341–346. doi: 10.1590/S0036-46652014000400012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rodríguez-Bano J., Navarro M.D., Romero L., Martínez-Martínez L., Muniain M.A., Perea E.J., Pérez-Cano R., Pascual A. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol. 2004;42:1089–1094. doi: 10.1128/JCM.42.3.1089-1094.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Santman-Berends I., Gonggrijp M., Hage J., Heuvelink A., Velthuis A., Lam T., van Schaik G. Prevalence and risk factors for extended-spectrum β-lactamase or AmpC-producing Escherichia coli in organic dairy herds in the Netherlands. J. Dairy Sci. 2017;100:562–571. doi: 10.3168/jds.2016-11839. [DOI] [PubMed] [Google Scholar]
- Tansawai U., Sanguansermsri D., Na-udom A., Walsh T.R., Niumsup P.R. Occurrence of extended spectrum β-lactamase and AmpC genes among multidrug-resistant Escherichia coli and emergence of ST131 from poultry meat in Thailand. Food Control. 2018;84:159–164. [Google Scholar]
- Welch R.A. Uropathogenic Escherichia coli-associated exotoxins. Microbiology spectrum. 2016;4 doi: 10.1128/microbiolspec.UTI-0011-2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wilkerson C., Samadpour M., Van Kirk N., Roberts M.C. Antibiotic resistance and distribution of tetracycline resistance genes in Escherichia coli O157: H7 isolates from humans and bovines. Antimicrob. Agents Chemother. 2004;48:1066–1067. doi: 10.1128/AAC.48.3.1066-1067.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R., Hart T., Cars O., Streulens M., Helmuth R., Huovinen P., Sprenger M. British Medical Journal Publishing Group; 1998. Antimicrobial Resistance. [DOI] [PMC free article] [PubMed] [Google Scholar]



